| 001 | 294684 | ||
| 005 | 20241127182726.0 | ||
| 024 | 7 | _ | |a 10.1093/noajnl/vdae155 |2 doi |
| 024 | 7 | _ | |a pmid:39582811 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC11582646 |2 pmc |
| 024 | 7 | _ | |a 2632-2498 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-02419 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Baugh, Joshua N |0 0000-0001-7281-6306 |b 0 |
| 245 | _ | _ | |a Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG Registry. |
| 260 | _ | _ | |a Oxford |c 2024 |b Oxford University Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1732692656_23889 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Our aim is to investigate the association of treatment with survival in patients with diffuse intrinsic pontine glioma (DIPG) by examining 6 historical treatment paths.We retrospectively analyzed data from 409 patients with radiologically centrally reviewed DIPG, sourced from the German Society of Pediatric Oncology and Hematology HIT-HGG trial database and the SIOPE-DIPG/DMG Registry. Survival outcomes were estimated using the Kaplan-Meier method, and univariable and multivariable Cox proportional hazard models were estimated to study treatment effects.The median overall survival (OS) from diagnosis was 11.2 months (95% confidence interval [CI], 10.5-11.9). Patients who by choice received no frontline treatment had an OS of 3.0 months (95% CI, 2.0-4.0), while those treated with radiation therapy (RT) alone had a median OS of 10.4 months (95% CI, 9.1-11.8). Those receiving RT combined with chemotherapy had the longest median OS of 11.7 months (95% CI, 10.8-12.6). The median post-progression survival (PPS) was 4.1 months (95% CI, 3.5-4.7). Patients who relapsed and did not receive treatment had a PPS of 2.2 months (95% CI, 1.8-2.6), while those treated with chemotherapy alone had a PPS of 4.4 months (95% CI, 3.7-5.0), and those who underwent reirradiation, with or without chemotherapy, had the longest survival after relapse of 6.6 months (95% CI, 5.3-8.0). Treatment differences remained significant in multivariable analysis adjusted for age and symptom duration in both diagnosis and relapse setting.This study shows increased survival outcomes associated with radiation and chemotherapy treatment or a combination thereof, at diagnosis and relapse, in a historical DIPG cohort. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a DIPG |2 Other |
| 650 | _ | 7 | |a diffuse intrinsic pontine glioma |2 Other |
| 650 | _ | 7 | |a diffuse midline glioma |2 Other |
| 650 | _ | 7 | |a historical control |2 Other |
| 650 | _ | 7 | |a registry |2 Other |
| 700 | 1 | _ | |a Veldhuijzen van Zanten, Sophie |b 1 |
| 700 | 1 | _ | |a Fiocco, Marta |b 2 |
| 700 | 1 | _ | |a Colditz, Niclas |b 3 |
| 700 | 1 | _ | |a Hoffmann, Marion |b 4 |
| 700 | 1 | _ | |a Janssens, Geert O |b 5 |
| 700 | 1 | _ | |a Valentini, Chiara |b 6 |
| 700 | 1 | _ | |a Hargrave, Darren |b 7 |
| 700 | 1 | _ | |a Wiese, Maria |b 8 |
| 700 | 1 | _ | |a von Bueren, André O |b 9 |
| 700 | 1 | _ | |a Karremann, Michael |b 10 |
| 700 | 1 | _ | |a Perwein, Thomas |b 11 |
| 700 | 1 | _ | |a Nussbaumer, Gunther |b 12 |
| 700 | 1 | _ | |a Benesch, Martin |b 13 |
| 700 | 1 | _ | |a Sturm, Dominik |0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807 |b 14 |u dkfz |
| 700 | 1 | _ | |a Gielen, Gerrit H |b 15 |
| 700 | 1 | _ | |a Krause, Mechthild |0 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9 |b 16 |u dkfz |
| 700 | 1 | _ | |a Eyrich, Matthias |b 17 |
| 700 | 1 | _ | |a Hoving, Eelco W |b 18 |
| 700 | 1 | _ | |a Bison, Brigitte |b 19 |
| 700 | 1 | _ | |a van Vuurden, Dannis G |b 20 |
| 700 | 1 | _ | |a Kramm, Christof M |b 21 |
| 773 | _ | _ | |a 10.1093/noajnl/vdae155 |g Vol. 6, no. 1, p. vdae155 |0 PERI:(DE-600)3009682-0 |n 1 |p vdae155 |t Neuro-oncology advances |v 6 |y 2024 |x 2632-2498 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:294684 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOL ADV : 2022 |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-11-23T11:49:35Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-11-23T11:49:35Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2022-11-23T11:49:35Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0112 |2 StatID |b Emerging Sources Citation Index |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-27 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-27 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-10-27 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-10-27 |
| 920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pädiatrische Gliomforschung |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)DD01-20160331 |k DD01 |l DKTK Koordinierungsstelle Dresden |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B360-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)DD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::